OnCore Login

News & Developments

Across the Consortium: February 2019

Feb. 19, 2019:

In this month’s Across the Consortium, the Big Ten CRC features the health initiatives our members are pursuing to reach communities at greatest risk of fatal cancer due to educational and health disparities; we celebrate some of the newest advances in cancer research at Big Ten universities; and we highlight our members’ engagement with state and local leaders.

Read More

Hrinczenko joins Big Ten CRC Steering Committee

Feb. 5, 2019: Borys Hrinczenko, MD, PhD, a lung cancer specialist at the Michigan State University Breslin Cancer Center, has been appointed to the Big Ten Cancer Research Consortium’s steering committee. As such, Dr. Hrinczenko, who has more than 20 years of experience in cancer research, will represent Michigan State University and help establish research priorities for the 12 member institutions of the Big Ten CRC. He currently is a member of the consortium’s Thoracic Clinical Trial Working Group. Dr.... Read More

Member Feature: Indiana University Melvin and Bren Simon Cancer Center

Feb. 1, 2019: Thought Leader Perspectives: Acute Myeloid Leukemia Acute myeloid leukemia (AML), a rapidly progressive form of blood cancer that can occur at any age but mostly presents in patients age 60 and older, represents the most common cause of leukemia-related mortality in the United States and accounts for approximately 21,000 new cases and 10,000 deaths per year. For decades, the therapeutic progress in AML has been slower than in other cancers, which is in part due to the enormous genomic heterogeneity of the disease. Although the approval of several targeted agents by the FDA since April 2017 inaugurated an exciting new era in AML therapy, only a subset of patients are expected to benefit from these tailored treatment options. The great progress in understanding the... Read More

Investigators report early efficacy results for esophageal/GEJ study

Jan. 23, 2019: Big Ten investigators presented early efficacy results of the BTCRC-ESO14-012 study during the 2019 Gastrointestinal Cancers Symposium, Jan. 17-19 in San Francisco. Read More

Across the Consortium: January 2019

Jan. 20, 2019: In this month's Across the Consortium, we highlight a variety of research initiatives — from genetic testing for quicker diagnosis to new projects that help us better understand biology in order to prevent and kill cancer faster — and we remember those who recently passed away and had a profound influence in cancer research and advocacy. Read More

Sors joins Big Ten CRC Steering Committee

Jan. 10, 2019: The Big Ten Cancer Research Consortium (Big Ten CRC) recently named Thomas G. Sors, PhD, assistant director of the Purdue Institute of Inflammation, Immunology and Infectious Disease (PI4D), to the Big Ten CRC Steering Committee, representing the Purdue University Center for Cancer Research. The Big Ten CRC Steering Committee comprises one representative from each member institution and meets regularly to review activities and guide policies for the consortium. Read More

Across the Consortium: December 2018

Dec. 20, 2018: In this month's Across the Consortium, we are inspired by Big Ten cancer researchers making significant discoveries in improving treatment and quality of life for cancer patients. We also recognize those who have received grants for their work. Read More

Member Feature: Fred & Pamela Buffett Cancer Center

Dec. 1, 2018: Investigator Spotlight Pavankumar Tandra, MBBS, Fred & Pamela Buffett Cancer Center (University of Nebraska) Educational background MBBS: Osmania Medical School MRCGP: South East Scotland Deanery Fellowship (Hematology-Oncology): University of Nebraska Medical Center Research interests My research interests include tailoring the systemic therapies for early stage HER2-positive breast cancer. I believe we should do more studies in the neoadjuvant platform to assess the strengths of new targeted drugs, to identify biomarkers and minimize the toxicity from chemotherapy. It is very promising to see the new drugs studied... Read More

Dr. Kari Wisinski joins Steering Committee

Nov. 20, 2018: Kari Wisinski, MD, a breast cancer specialist with the UW Carbone Cancer Center, has been named to the Steering Committee of the Big Ten Cancer Research Consortium (Big Ten CRC). In that role, she will serve as the University of Wisconsin-Madison representative, helping shape the research priorities of the Big Ten CRC. She currently is the co-chair of the consortium's Breast Cancer Clinical Trial Working Group. Read More

Study of plinabulin, and nivolumab + ipilimumab in SCLC now open

Rutgers trial aims to demonstrate reduction in immune-related adverse events, while adding to anti-cancer immune effects for patients Nov. 15, 2018: BeyondSpring Inc. recently announced the opening of an investigator-initiated Phase 1 clinical trial with a triple combination therapy, consisting of BeyondSpring’s lead asset, plinabulin, and Bristol-Myers Squibb's Opdivo (nivolumab) and Yervoy (ipilimumab) for the treatment of small-cell lung cancer (SCLC). The trial (BTCRC-LUN17-127), conducted through the Big Ten Cancer Research Consortium (Big Ten CRC), is currently enrolling subjects at Rutgers Cancer Institute of New Jersey. Jyoti Malhotra, MD, MPH, medical... Read More

University of Illinois

University of Illinois

Indiana University

Indiana University

University of Iowa

University of Iowa

University of Maryland

University of Maryland

University of Michigan

University of Michigan

Michigan State

Michigan State

University of Minnesota

University of Minnesota

University of Nebraska

University of Nebraska

Northwestern University

Northwestern University

Penn State University

Penn State University

Purdue University

Purdue University

Rutgers State University

Rutgers State University

University of Wisconsin

University of Wisconsin

University of Illinois at Chicago

University of Illinois at Chicago

© 2024 All rights reserved.

Big Ten Cancer Research Consortium
7676 Interactive Way, Suite 120, Indianapolis, IN 46278

email: info@bigtencrc.org    phone: 317–921–2050